Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplant. 2018 Sep;53(9):1218-1220. doi: 10.1038/s41409-018-0182-9. Epub 2018 Apr 26.

Authors

Kyle R Brownback¹, Lucas R Pitts², Sunil Abhyankar³

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, University of Kansas Medical Center, Kansas City, KS, USA. kbrownback@kumc.edu.
² Division of Pulmonary and Critical Care Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
³ Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.

PMID: 29700478
DOI: 10.1038/s41409-018-0182-9

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Allografts
Graft vs Host Disease* / diagnostic imaging
Graft vs Host Disease* / drug therapy
Hematopoietic Stem Cell Transplantation*
Humans
Indoles / administration & dosage*
Indoles / adverse effects
Lymphoma, T-Cell, Peripheral* / diagnostic imaging
Lymphoma, T-Cell, Peripheral* / therapy
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / diagnostic imaging
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Pulmonary Fibrosis* / diagnostic imaging
Pulmonary Fibrosis* / drug therapy
Pulmonary Fibrosis* / etiology

Substances

Indoles
nintedanib